Market Cap: $643.9B
JJ
Johnson & Johnson
JNJ
NYSE (New York Stock Exchange)USD
Market Cap: $643.9B
Johnson & Johnson ( JNJ ) is navigating a pivotal juncture as it dramatically reshapes its business strategy towards oncology, guided by evolving healthcare demands and the urgent need for innovative…
Johnson & Johnson ( JNJ ) is at a pivotal juncture as it strategically pivots towards the oncology sector. This shift is not merely a change in product focus; it reflects a response to the escalating…
Johnson & Johnson (JNJ) has been making significant strides in refocusing its business strategy towards oncology, highlighted by groundbreaking product innovations and strategic acquisitions aimed at…
Johnson & Johnson (Ticker: JNJ) positions itself as a front-runner in the oncology landscape with significant strides regarding its cancer treatment innovation. The European Medicines Agency’s committ…
Johnson & Johnson (Ticker: JNJ) presents new encouraging data on IMAAVY® (nipocalimab-aahu), showcasing its potential in treating generalized myasthenia gravis (gMG) at the European Academy of Neurolo…
Johnson & Johnson (Ticker: JNJ) is undergoing a notable transformation in its strategic priorities as it shifts focus from the obesity drug market to cancer treatments. This decision underscores the c…
Johnson & Johnson (Ticker: JNJ) makes notable strides in oncology with its innovative bispecific antibody TALVEY, which presents promising results in the treatment of relapsed/refractory multiple myel…
Johnson & Johnson (Ticker: JNJ) announces the U.S. launch of its TECNIS PureSee intraocular lens, a groundbreaking development in vision correction for cataract patients. Designed specifically for tho…
Johnson & Johnson (Ticker: JNJ) advances its position in the healthcare sector with promising results from its drug IMAAVY, an innovative treatment for warm autoimmune hemolytic anemia (wAIHA). The Ph…
Johnson & Johnson (Ticker: JNJ) makes strides in the healthcare industry with promising advances in its drug development pipeline, particularly with nipocalimab. Recent data from clinical trials showc…
Johnson & Johnson (Ticker: JNJ) announces a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of a supplemental Biologics License Application for its medication TREMFYA…
Johnson & Johnson (Ticker: JNJ) is advancing its portfolio in cardiovascular treatment through the recent launch of the Shockwave C2 Aero coronary intravascular lithotripsy catheter. This innovative d…
Johnson & Johnson (Ticker: JNJ) has recently announced significant advancements in the treatment of inflammatory bowel diseases (IBD), showcasing its commitment to addressing unmet medical needs in th…
Johnson & Johnson (NYSE: JNJ) has made a significant move in the MedTech sector with its recent acquisition of Atraverse Medical, a company known for its transseptal access solutions designed for mini…
Johnson & Johnson (JNJ) demonstrates promising advancements in the treatment of generalized myasthenia gravis (gMG) with the results from the Phase 3 Vivacity-MG3 study. The study reports long-term ef…
Johnson & Johnson (NYSE: JNJ) reports strong first-quarter earnings that significantly exceed market expectations. The healthcare giant announces a revenue of $24.75 billion, showing an increase compa…
Innovative Partnership to Combat Advanced Prostate Cancer Johnson & Johnson enters a significant clinical supply agreement with GI Innovation, focusing on a combination therapy aimed at treating metas…
Johnson & Johnson Adapts to New Psoriasis Treatment Landscape Following FDA Approval In a notable advancement for dermatological treatments, the U.S. Food and Drug Administration (FDA) has recently ap…
Innovative Oral Solution for Psoriasis: Johnson & Johnson's Icotyde Approved Johnson & Johnson (J&J) celebrates the FDA approval of Icotyde, a groundbreaking oral medication designed to treat moderate…
### Johnson & Johnson Launches Innovative Oral Treatment for Psoriasis Johnson & Johnson (J&J) has revolutionized the treatment landscape for moderate to severe plaque psoriasis with the recent FDA ap…
Johnson & Johnson Introduces Innovative Oral Psoriasis Treatment Johnson & Johnson (J&J) recently receives FDA approval for Icotyde, a once-daily oral medication designed to treat moderate to severe p…
Johnson & Johnson Advances in Bladder Cancer Treatment with Innovative Drug Delivery System Johnson & Johnson's recent advancements in bladder cancer treatment highlight a significant step forward in…
Johnson & Johnson Advances Bladder Cancer Treatment with Promising Study Results Johnson & Johnson (NYSE: JNJ) makes significant strides in the quest for innovative cancer therapies with the recent an…
FDA Expands Approval of Wellcovorin: A Breakthrough for Cancer Treatment On Tuesday, the U.S. Food and Drug Administration (FDA) announced the expanded approval of Wellcovorin (leucovorin calcium) tab…
FDA Approves Expanded Use of Wellcovorin: A Landmark Development for Oncology Treatment The U.S. Food and Drug Administration (FDA) recently grants expanded approval for Wellcovorin (leucovorin calciu…